Cabozantinib Caboxen 80mg

Product Name: Caboxen

Generic Name: Cabozantinib

Dosage Form: Capsules

Specification: 80 mg/capsule; 90 capsules/bottle

Manufacturer: Everest Medicines

Cabozantinib is a multi-targeted, broad-spectrum anticancer drug capable of inhibiting at least nine distinct targets, including MET, VEGFR1/2/3, ROS1, RET, AXL, NTRK, and KIT.

Currently, Cabozantinib has demonstrated significant therapeutic efficacy across a wide range of solid tumors, including renal cell carcinoma, thyroid cancer, hepatocellular carcinoma, soft tissue sarcoma, non-small cell lung cancer, prostate cancer, breast cancer, ovarian cancer, and colorectal cancer. It is particularly effective in controlling bone metastases. Due to its broad efficacy against multiple cancer types, Cabozantinib is often referred to as the "universal remedy" among targeted therapies, possessing broad-spectrum anticancer capabilities.

Treatment of Renal Cell Carcinoma: The response rate of Cabozantinib is several times higher than that of Sutent (46% vs. 18%), and it significantly extends overall survival (30.3 months vs. 21.8 months). The side effect profiles of the two drugs are very similar, with adverse event rates of 67% and 68%, respectively. The primary side effects include diarrhea, fatigue, hypertension, and hand-foot syndrome. Currently, Cabozantinib has become a first-line treatment of choice for advanced renal cell carcinoma.

Treatment of Hepatocellular Carcinoma: In patients with advanced hepatocellular carcinoma treated with Cabozantinib, overall survival was significantly prolonged, and the risk of death was reduced by 37%. The objective response rate is approximately 5%. Currently, alongside drugs such as Regorafenib and PD-1 antibodies, Cabozantinib has established itself as a key therapeutic option for advanced hepatocellular carcinoma.

Treatment of Lung Cancer: Among patients with non-small cell lung cancer (NSCLC), approximately 2% harbor *RET* gene rearrangements. These patients are eligible for treatment with Cabozantinib. In 2016, the prestigious medical journal *The Lancet Oncology* published clinical trial data regarding the use of Cabozantinib in lung cancer patients with *RET* rearrangements: among 26 patients, the objective response rate was 28%, and the disease control rate approached 100%. Furthermore, for lung cancer patients with EGFR wild-type tumors who have failed first-line therapy, treatment with Cabozantinib in combination with Tarceva (Erlotinib) resulted in a significantly longer survival duration compared to either agent used alone. The median survival in the combination therapy group was 13.3 months, compared to 9.2 months in the Cabozantinib monotherapy group and 5.1 months in the Tarceva monotherapy group.

Treatment of Thyroid Cancer: For thyroid cancer patients harboring *RET* mutations, Cabozantinib significantly extended overall survival, increasing it from 18.9 months to 44.3 months—more than a twofold increase. In the overall patient population, overall survival also improved from 21.1 months to 26.6 months.

Cabozantinib targets a multitude of molecular pathways; some of these targets are implicated in the formation of bone metastases. Consequently, the drug demonstrates excellent efficacy in controlling bone metastases associated with solid tumors and has been widely adopted for the treatment of bone metastases in patients with renal cell carcinoma and prostate cancer.

Cabozantinib can enhance the efficacy of immunotherapies—such as PD-1 antibodies—by mechanisms that include eliminating "myeloid-derived suppressor cells" (MDSCs) located within the tumor microenvironment, which otherwise act to facilitate tumor growth. As a result, numerous studies have identified Cabozantinib as an "ideal partner" for PD-1 antibodies in combination therapy regimens, yielding favorable clinical outcomes.

In 2012, the U.S. FDA approved Cabozantinib capsules (140 mg/day) for the treatment of progressive, metastatic medullary thyroid carcinoma (MTC). Subsequently, in April 2016, the FDA approved Cabozantinib tablets (60 mg/day) for the treatment of advanced renal cell carcinoma (RCC) in patients who had previously received anti-angiogenic therapy.

In January 2019, the U.S. FDA approved Cabozantinib tablets (60 mg/day) for the treatment of advanced hepatocellular carcinoma (HCC) in patients whose disease had progressed following treatment with other standard systemic therapies, such as Lenvatinib or Sorafenib.

As a second-line therapeutic agent for liver cancer, Cabozantinib tablets can significantly prolong survival in patients with HCC, reducing the risk of death or disease progression by 56%. The prognosis for patients with advanced hepatocellular carcinoma (HCC) is often poor, and treatment options become limited following systemic therapy. The CELESTIAL trial demonstrated that Cabozantinib tablets significantly improved overall survival in patients with advanced HCC; progression-free survival and objective response rates also saw significant improvements, establishing it as a new therapeutic option for patients with liver cancer.

China bears a massive burden of liver cancer; Chinese patients account for over 50% of all newly diagnosed cases globally each year, with hepatitis B virus (HBV) infection being the most common underlying cause. Due to the insidious nature of the disease, most cases of liver cancer are already in an advanced stage by the time they are detected. The approval of Cabozantinib tablets for the treatment of liver cancer brings new hope to patients in China.

To ensure safe medication use, please exercise caution and consult with a healthcare professional when making your choice.

**Indications:**

Cabozantinib has a broad range of indications, primarily including:

(1) Advanced renal cell carcinoma (kidney cancer) in patients who have previously received anti-angiogenic therapy;

(2) Medullary thyroid carcinoma that is not amenable to surgical resection;

(3) Hepatocellular carcinoma (liver cancer) in patients who have developed resistance to Sorafenib (Nexavar);

(4) Advanced prostate cancer with bone metastases.

**Dosage and Administration:**

(1) The recommended dosage is 140 mg daily (consisting of one 80 mg capsule and three 20 mg capsules);

(2) The medication must not be taken with food;

(3) Patients should refrain from eating for at least 2 hours—specifically, for at least one hour before taking the medication and for at least one hour after taking it;

(4) In the event of adverse reactions, dose reduction or temporary interruption of treatment may be considered.

**Common Side Effects:**

Diarrhea, nausea, vomiting, constipation, oral mucositis (mouth sores), epistaxis (nosebleeds), decreased appetite, etc. **Product Specifications**

**Product Name:** Cabozantinib 80mg (30 Capsules) — Everest Caboxen 80mg

**Common Name:** Cabozantinib

**Active Ingredient:** Cabozantinib

**Dosage Form:** Capsules

**Specification:** 80mg/capsule; 90 capsules/bottle

**Manufacturer:** Everest Pharmaceuticals

**Indications:** Cabozantinib has a broad range of indications, primarily including:

(1) Advanced renal cell carcinoma (kidney cancer) in patients who have previously received anti-angiogenic therapy;

(2) Medullary thyroid carcinoma that is not amenable to surgical resection;

(3) Hepatocellular carcinoma (liver cancer) in patients who have developed resistance to Sorafenib (Nexavar);

(4) Advanced prostate cancer in patients with bone metastases.

**Usage and Dosage:**

(1) The recommended dosage is 140mg daily (consisting of one 80mg capsule and three 20mg capsules);

(2) Must not be taken with food;

(3) Do not consume food for at least 2 hours—specifically, for at least one hour before taking the medication and for at least one hour after taking it;

(4) In the event of adverse reactions, dose reduction or temporary interruption of treatment may be considered.